Regeneron Stock Sinks on Disappointing Sales of Eylea Treatment

Regeneron Pharmaceuticals

inventory was tumbling after the drugs maker reported decrease gross sales of its Eylea therapy than Wall Road was anticipating for the fourth quarter.

In a preliminary replace on its fourth quarter on Monday,


(REGN) mentioned fourth-quarter gross sales of Eylea have been $1.5 billion. The consensus name amongst analysts tracked by FactSet was for $1.64 billion, whereas the year-earlier determine was $1.55 billion.

Leave a Comment

Copyright © 2024. All Rights Reserved. Finapress | Flytonic Theme by Flytonic.